STOCK TITAN
  1. Home
  2. News
  3. AGEN

Agenus Inc - AGEN STOCK NEWS

Welcome to our dedicated news page for Agenus (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Agenus's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Agenus's position in the market.

News
Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population
Rhea-AI Summary
Agenus Inc. announces groundbreaking results from the NEST-1 study, showing significant tumor regression and complete elimination of ctDNA in patients with localized MSS Colorectal Cancer. The study highlights the potential impact of botensilimab and balstilimab in neoadjuvant treatment, offering a transformative approach for CRC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
none
-
News
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Agenus Inc. (AGEN) announces inducement awards to Manuel Duenas and Benny Johnson for their appointments as Head of Market Access and Senior Medical Director, respectively. The awards consist of options to purchase shares of Agenus common stock and restricted stock units, subject to vesting conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Agenus to Participate in B. Riley Healthcare Conference
Rhea-AI Summary
Agenus Inc. (Nasdaq: AGEN) announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming B. Riley Virtual Healthcare Conference on January 18th. The fireside chat will take place at 3:00 p.m. ET on January 18th. To access this event, please RSVP to your B. Riley Securities sales representative. Following the event, a replay of the fireside chat will be posted to the company’s website at https://investor.agenusbio.com/events-and-presentations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
conferences
News
Botensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024
Rhea-AI Summary
Agenus Inc. (Nasdaq: AGEN) announces the presentation of data from an investigator sponsored trial (IST) evaluating botensilimab (BOT) in combination with balstilimab (BAL) in neoadjuvant colorectal cancer (CRC) at the upcoming ASCO-GI Meeting. The IST is led by Pashtoon Kasi, M.D., and the presentation will be on January 20, 2024, at 6:30am – 7:55am EST.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
none
-
News
Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program
Rhea-AI Summary
Agenus Inc. (Nasdaq: AGEN) triggers second development milestone payment with Bristol Myers Squibb for BMS-986442, an Fc-enhanced bispecific TIGIT antibody. Agenus to receive $25 million cash payment with dosing of first patient in phase 2 dose expansion portion of CA115-001 clinical trial. Potential $1.32 billion in additional milestones and royalties. Bristol Myers Squibb solely responsible for development and commercialization worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.33%
Tags
none
-
News
Agenus Reports Third Quarter 2023 Results
Rhea-AI Summary
Agenus Inc. announced results for the third quarter 2023, with promising data on botensilimab (BOT) and balstilimab (BAL) in treating advanced solid tumors. A Biologics License Application for microsatellite stable (MSS) metastatic CRC is expected in mid-2024. The company also reported a net loss of $64.5 million for the third quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.13%
Tags
earnings
News
Agenus to Provide Third Quarter 2023 Financial Report and Corporate Update
Rhea-AI Summary
Agenus Inc. to release Q3 2023 financial results on November 7, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
earnings
-
News
Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma
Rhea-AI Summary
Agenus Inc. plans to file a Biologics License Application (BLA) for its botensilimab/balstilimab (BOT/BAL) combination therapy in midyear 2024 for the treatment of metastatic colorectal cancer (CRC). The therapy has shown improved responses and durability in refractory MSS CRC patients. It also demonstrated promising clinical outcomes in neoadjuvant MSS CRC patients. The company is evaluating further regulatory activity for neoadjuvant development. In addition, the therapy showed compelling activity in relapsed/refractory advanced pancreatic cancer, melanoma, non-small cell lung cancer (NSCLC), and sarcoma. The webcast discussing the findings will be held at the European Society for Medical Oncology 2023 Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes
Rhea-AI Summary
Agenus Inc. presents expanded data from phase 1b study of botensilimab and balstilimab in patients with advanced sarcomas
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Agenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer
Rhea-AI Summary
Agenus completes patient enrollment in phase 2 trial for advanced colorectal cancer treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
clinical trial
Stock AGEN logo
Agenus Inc

Nasdaq:AGEN

AGEN Rankings

#4039 Ranked by Market Cap
#5098 Ranked by Stock Gains
N/A Ranked by Dividends

AGEN Stock Data

131.96M
17.69M
1.2%
59.18%
11.39%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Lexington

About AGEN

agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases. our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. our approaches are driven by three platform technologies, including: • our antibody platforms, including our proprietary retrocyte display™ and secant® technologies, and our antibody